Coherus BioSciences shares are trading higher after Baird initiated coverage on the stock with an Outperform rating and announced an $11 price target.
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences' stock is trading higher following an Outperform rating initiation and an $11 price target from Baird.
November 17, 2023 | 5:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird initiated coverage on Coherus BioSciences with an Outperform rating and a price target of $11, leading to a rise in the stock's trading price.
Analyst ratings, especially from reputable firms like Baird, can significantly influence investor sentiment and stock prices. The Outperform rating and the $11 price target suggest a positive outlook for Coherus BioSciences, which is likely to attract investors and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100